



Updated! ON Biosimilar Support Fee

Switching Patients from Biologics to Biosimilars

Effective **July 31, 2024**, the biosimilar policy will be updated to include the following four biologic drugs:

- Lucentis[®] (ranibizumab)
- Stelara[®] (ustekinumab)
- Lovenox[®] (enoxaparin)
- **Neupogen**[®] (filgrastim)

On **February 1, 2025**, coverage for the above biologics will cease. To maintain uninterrupted coverage, patients need to be transitioned to a biosimilar, barring any medically necessary exemptions.

Pharmacies can claim a Biosimilar Support Fee for filling the first biosimilar prescription for an Ontario Drug Benefit (ODB) patient who is transitioning from a biologic listed above or discussing the transition with a patient's prescriber and getting a new prescription. The claim must be submitted between July 31, 2024, and January 30, 2026.

Locating the Biosimilar Support Fee Drug Folders

A Drug Folder has been created for each Biosimilar Support Fee PIN. To locate them, you can search using one or more of the following attributes:

• **Trade or Generic Name** – all Drug Folders contain "biosimilar support fee" in the trade and generic name.



TIP: When you're searching for a word or phrase in a trade or generic name and it's not the first word or phrase in the name, enter a "%" before your search words to perform a wildcard search.

For example, to search for the Biosimilar Support Fee Drug Folders, enter "%biosimilar support fee".

- Strength the strength corresponds to the generic name for the biosimilar.
- PIN refer to the table below for the list of ODB PINs.

Table 1. Biosimilar Support Fee PINs for ODB.

PIN	Trade and Generic Name	Strength
9858337	ASSESS & PRSCRBE: BIOSIMILAR SUPPORT FEE	RANBIZUMAB
9858338		USTEKNUMAB
9858339		ENOXAPARIN
9858340		FILGRASTIM





Submitting the Biosimilar Support Fee Claim

To process the Biosimilar Support Fee claim:

- 1. Select New from the Workbench or Patient Profile.
- 2. Enter the following information in the **New Prescription** window:
 - Patient
 - Drug = PIN

NOTE: You can submit a maximum of one claim per patient per transition to a biosimilar version of a biologic.

- **Doctor** = pharmacist
- Qty Auth = 1
- **Qty** = 1
- SIG

•

- Days Supl
- 3. Select **Process Now**. Rx Detail opens.
- 4. In the **Price** section, confirm the following:
 - Cost and Markup = \$0
 - Fee = \$15
- 5. Select the **Third Party** tab.
- 6. Confirm a PS intervention code is entered for Drug Benefit.
- 7. Select Fill.

Additional Resources

- <u>Executive Officer Notice: Biosimilar Policy</u>
- Biosimilar Policy: Q&A for Pharmacists





.....

Frequently Asked Questions

The fee is not populating correctly when I process a prescription for a Biosimilar Support Fee PIN. What should I do?

The pricing for a Biosimilar Support Fee PIN is controlled by a Custom Class and Pricing Rule in PharmaClik Rx. These should be set up automatically for you by July 31, 2024. However, if pricing is not populating correctly, perform the following checks.

Part 1. Check the Drug Folder for the Custom Class

- 1. Open the **Drug Folder** for the Biosimilar Support Fee PIN (<u>Table 1</u>).
- 2. Select the Alternatives tab.
- 3. Confirm there is a Custom Class row for Drug Benefit exactly as shown below.

Custom Class			
Third Party Plan	Custom Class		Add
Drug Benefit - All	Pharmaceutical Opinion	T	
			Remove
1			

If the row already exists, proceed to Part 2. If the row does NOT exist, proceed to step 4.

- 4. Select Add.
- 5. Enter the following information:
 - Third Party Plan = Drug Benefit All
 - **Custom Class** = Pharmaceutical Opinion
- 6. Select **Save**.

Part 2. Check the Pricing Rule

- 1. Select More > Pharmacy.
- 2. Select the Pricing tab.
- 3. Underneath the **Drug Benefit** row, confirm there is a sub-row for Pharmaceutical Opinion exactly as shown below.



If the row does not exist, proceed to step 4.

4. Highlight the Drug Benefit row.





.....

- 5. Select Add CC. The Select Custom Class window opens.
- 6. Highlight Pharmaceutical Opinion.
- 7. Select OK.
- 8. In the Pharmaceutical Opinion row, enter the following:
 - Fee = \$15.00
 - **Markup** = 0.0%
- 9. Select **Save**.

I want to generate a list of patients that are taking a biologic drug under the biosimilar policy to give to a prescriber. What report should I use?

There are several reports that be generated to obtain this information. Two such reports include the Patient List and Analysis by Drug.

- Patient List allows you to generate the report for one drug at a time for a specific prescriber. Please note, this report will include information about the number of prescriptions dispensed and their dollar volume. For more information, see <u>Patient List</u> <u>Report</u>.
- Analysis By Drug allows you to generate the report for multiple drugs at a time. The report includes columns for Quantity Authorized and Quantity Dispensed for a prescription. If you need to generate the report for a specific prescriber, you can save the report as a .CSV with Headers file and filter by the "doctor_name" column in a spreadsheet application. For more information, see <u>Analysis by Drug Report</u> and <u>Exporting Reports to Spreadsheet Applications</u>.

